Laurence Legout
Research Subjects
Laurence Legout has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
E. Senneville
4 shared publicationsEric Senneville
Infectious diseases department, Dron hospital, Tourcoing, France
3 shared publicationsB. Sarraz-Bournet
Department of Vascular Surgery, Dron Hospital of Tourcoing, Tourcoing, France
2 shared publicationsO. Leroy
Intensive Care and Infectious Diseases Unit, Dron Hospital of Tourcoing, Tourcoing, France
2 shared publicationsS. Haulon
Microbiology Laboratory, University Hospital of Lille, Lille, France
2 shared publicationsY. Yazdanpanah
Infectious Diseases Department, Tourcoing, France
2 shared publications
Latest Publications
- Open Access
- 4 September 2014
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 3 (2) , 215-223
Tolerability of High Doses of Daptomycin in the Treatment of Prosthetic Vascular Graft Infection: A Retrospective Study
Introduction In treatment of prosthetic vascular graft infection (PVGI), appropriate antimicrobial treatment is crucial for controlling the septic process and preventing re-infection of the new graft. Glycopeptides are the mainstay of treatment for device-related infections by methicillin-resistant Staphylococcus aureus strains, but with some limitations, especially concerning vancomycin-intermediate and glycopeptide-intermediate S. aureus. We report our experience using a high dose of daptomycin (DAP) for treatment of PVGI. Methods We reviewed medical reports of 26 patients treated with high doses of DAP (>8 mg/kg) and beta-lactams/aminosides for PVGI, defined as positive bacterial culture of intraoperative specimens or blood samples and/or clinical, biological, and radiological signs of infection. Clinical success was defined by resolution of all clinical signs at the end of follow-up, without the need for additional antibiotic therapy, and/or negative culture in case of new surgery. Results Cultures of intraoperative samples were positive in 21 patients (80.8%). Blood and intraoperative cultures were concomitantly positive in 10 patients. The main microorganism identified in microbiological samples was S. aureus (n = 18). Surgery was performed in 23 patients (88.4%). The mean duration of the DAP regimen was 12.3 ± 11.9 days. DAP was discontinued in 26 patients [need to switch to microbiological results (n = 19), bacterial pneumonia (n = 2), and increased creatine phosphokinase levels (n = 4)]. One patient had myalgia, while 9 received concomitant statins. Conclusion High-dose DAP therapy shows a satisfactory toxicity profile even in severely ill patients with multiple comorbidities, and may favorably compete with vancomycin, especially concerning the risk of induced nephrotoxicity.
- 4 September 2014
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 3 (2) , 215-223
Open AccessTolerability of High Doses of Daptomycin in the Treatment of Prosthetic Vascular Graft Infection: A Retrospective Study
Introduction In treatment of prosthetic vascular graft infection (PVGI), appropriate antimicrobial treatment is crucial for controlling the septic process and preventing re-infection of the new graft. Glycopeptides are the mainstay of treatment for device-related infections by methicillin-resistant Staphylococcus aureus strains, but with some limitations, especially concerning vancomycin-intermediate and glycopeptide-intermediate S. aureus. We report our experience using a high dose of daptomycin (DAP) for treatment of PVGI. Methods We reviewed medical reports of 26 patients treated with high doses of DAP (>8 mg/kg) and beta-lactams/aminosides for PVGI, defined as positive bacterial culture of intraoperative specimens or blood samples and/or clinical, biological, and radiological signs of infection. Clinical success was defined by resolution of all clinical signs at the end of follow-up, without the need for additional antibiotic therapy, and/or negative culture in case of new surgery. Results Cultures of intraoperative samples were positive in 21 patients (80.8%). Blood and intraoperative cultures were concomitantly positive in 10 patients. The main microorganism identified in microbiological samples was S. aureus (n = 18). Surgery was performed in 23 patients (88.4%). The mean duration of the DAP regimen was 12.3 ± 11.9 days. DAP was discontinued in 26 patients [need to switch to microbiological results (n = 19), bacterial pneumonia (n = 2), and increased creatine phosphokinase levels (n = 4)]. One patient had myalgia, while 9 received concomitant statins. Conclusion High-dose DAP therapy shows a satisfactory toxicity profile even in severely ill patients with multiple comorbidities, and may favorably compete with vancomycin, especially concerning the risk of induced nephrotoxicity.
- 1 September 2014
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 26 (9) , 672-675
Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess
We report an unusual case of pulmonary aspergillosis in a patient with AIDS and we demonstrated the drug-drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine. The combination darunavir-ritonavir-voriconazole should be avoided.
- 1 September 2014
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 26 (9) , 672-675
Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess
We report an unusual case of pulmonary aspergillosis in a patient with AIDS and we demonstrated the drug-drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine. The combination darunavir-ritonavir-voriconazole should be avoided.
- Open Access
- 28 April 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 228
Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin
There exists considerable debate concerning management of prosthetic vascular graft infection (PVGI), especially in terms of antimicrobial treatment. This report studies factors associated with treatment failure in a cohort of patients with staphylococcal PVGI, along with the impact of rifampin (RIF).
- 28 April 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 228
Open AccessFactors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin
There exists considerable debate concerning management of prosthetic vascular graft infection (PVGI), especially in terms of antimicrobial treatment. This report studies factors associated with treatment failure in a cohort of patients with staphylococcal PVGI, along with the impact of rifampin (RIF).
- Open Access
- 1 January 2013
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 549091
Periprosthetic Joint Infections: Clinical and Bench Research
Prosthetic joint infection is a devastating complication with high morbidity and substantial cost. The incidence is low but probably underestimated. Despite a significant basic and clinical research in this field, many questions concerning the definition of prosthetic infection as well the diagnosis and the management of these infections remained unanswered. We review the current literature about the new diagnostic methods, the management and the prevention of prosthetic joint infections.
- 1 January 2013
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 549091
Open AccessPeriprosthetic Joint Infections: Clinical and Bench Research
Prosthetic joint infection is a devastating complication with high morbidity and substantial cost. The incidence is low but probably underestimated. Despite a significant basic and clinical research in this field, many questions concerning the definition of prosthetic infection as well the diagnosis and the management of these infections remained unanswered. We review the current literature about the new diagnostic methods, the management and the prevention of prosthetic joint infections.
- 1 December 2012
- Published by Elsevier in Orthopaedics & Traumatology: Surgery & Research
- Vol. 98 (8) , 910-914
Antibiotic prophylaxis to reduce the risk of joint implant contamination during dental surgery seems unnecessary
- 1 December 2012
- Published by Elsevier in Orthopaedics & Traumatology: Surgery & Research
- Vol. 98 (8) , 910-914
Antibiotic prophylaxis to reduce the risk of joint implant contamination during dental surgery seems unnecessary
- Open Access
- 1 April 2012
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 18 (4) , 352-358
Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study
- 1 April 2012
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 18 (4) , 352-358
Open AccessCharacteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study
- 1 March 2012
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 42 (3) , 102-109
Diagnosis and management of prosthetic vascular graft infections
- 1 March 2012
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 42 (3) , 102-109
Diagnosis and management of prosthetic vascular graft infections
- Open Access
- 1 January 2012
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 11 (1) , 4
First Initial community-acquired meningitis due to extended-spectrum beta-lactamase producing Escherichia coli complicated with multiple aortic mycotic aneurysms
We report the first case of extended-spectrum beta-lactamase producingE. colicommunity-acquired meningitis complicated with multiple aortic mycotic aneurysms. Because of the acute aneurysm expansion with possible impending rupture on 2 abdominal CT scan, the patient underwent prompt vascular surgery and broad spectrum antibiotic therapy but he died of a hemorrhagic shock. Extended-spectrum beta-lactamase producingE. coliwas identified from both blood and cerebrospinal fluid culture before vascular treatment. The present case report does not however change the guidelines of Gram negative bacteria meningitis in adults.
- 1 January 2012
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 11 (1) , 4
Open AccessFirst Initial community-acquired meningitis due to extended-spectrum beta-lactamase producing Escherichia coli complicated with multiple aortic mycotic aneurysms
We report the first case of extended-spectrum beta-lactamase producingE. colicommunity-acquired meningitis complicated with multiple aortic mycotic aneurysms. Because of the acute aneurysm expansion with possible impending rupture on 2 abdominal CT scan, the patient underwent prompt vascular surgery and broad spectrum antibiotic therapy but he died of a hemorrhagic shock. Extended-spectrum beta-lactamase producingE. coliwas identified from both blood and cerebrospinal fluid culture before vascular treatment. The present case report does not however change the guidelines of Gram negative bacteria meningitis in adults.
- Open Access
- 29 July 2010
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (10) , 2224-2230
Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?
Linezolid therapy has shown high rates of clinical success in patients with osteomyelitis and prosthetic joint infections caused by Gram-positive cocci. Recent studies have demonstrated that linezolid/rifampicin combination therapy prevents the emergence of rifampicin-resistant mutations in vitro. However, linezolid/rifampicin combination-related haematological and neurological toxicities have not been evaluated. To assess the tolerability of prolonged linezolid/rifampicin combination therapy compared with other linezolid-containing regimens in patients with bone and joint infections. We reviewed the medical records of 94 patients who had received linezolid for >4 weeks after bone and joint infections. Anaemia was defined as a ≥2 g/dL reduction in haemoglobin, leucopenia as a total leucocyte count 9/L, and thrombocytopenia as a reduction in platelet count to P < 0.01). In multivariate analysis, age and treatment group were independently associated with anaemia. Thrombocytopenia was reported in 44% of patients on linezolid/rifampicin combination therapy, in 48% of patients on linezolid alone and in 57.7% of patients on other linezolid-containing regimens. Age was the only variable associated with thrombocytopenia (P = 0.019) in univariate analysis. Linezolid/rifampicin combination therapy was associated with a significantly reduced incidence of anaemia among patients with bone and joint infections, but it did not have an effect on thrombocytopenia and peripheral neuropathy rates. Linezolid/rifampicin combination therapy was not associated with poor clinical outcomes.
- 29 July 2010
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (10) , 2224-2230
Open AccessTolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?
Linezolid therapy has shown high rates of clinical success in patients with osteomyelitis and prosthetic joint infections caused by Gram-positive cocci. Recent studies have demonstrated that linezolid/rifampicin combination therapy prevents the emergence of rifampicin-resistant mutations in vitro. However, linezolid/rifampicin combination-related haematological and neurological toxicities have not been evaluated. To assess the tolerability of prolonged linezolid/rifampicin combination therapy compared with other linezolid-containing regimens in patients with bone and joint infections. We reviewed the medical records of 94 patients who had received linezolid for >4 weeks after bone and joint infections. Anaemia was defined as a ≥2 g/dL reduction in haemoglobin, leucopenia as a total leucocyte count 9/L, and thrombocytopenia as a reduction in platelet count to P < 0.01). In multivariate analysis, age and treatment group were independently associated with anaemia. Thrombocytopenia was reported in 44% of patients on linezolid/rifampicin combination therapy, in 48% of patients on linezolid alone and in 57.7% of patients on other linezolid-containing regimens. Age was the only variable associated with thrombocytopenia (P = 0.019) in univariate analysis. Linezolid/rifampicin combination therapy was associated with a significantly reduced incidence of anaemia among patients with bone and joint infections, but it did not have an effect on thrombocytopenia and peripheral neuropathy rates. Linezolid/rifampicin combination therapy was not associated with poor clinical outcomes.